Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME and Bioavailability of LY4100511 in Healthy Males
NCT06627088Phase 1Completed
- Sponsor
- DICE Therapeutics
- Start
- Aug 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of simepdekinra in plaque psoriasis (2 arms), sponsored by DICE Therapeutics. Primary endpoints: Total Radioactivity Recovery and Excretion (TRA), Area Under the Concentration from Time 0 to Infinity (AUC0-∞) for [14C] LY4100511 and 27 more. Started Aug 2024; status: completed.
02
Drugs
simepdekinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06627088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06627088.